Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines

2021; Multidisciplinary Digital Publishing Institute; Volume: 13; Issue: 11 Linguagem: Inglês

10.3390/v13112127

1999-4915

William Marciel de Souza, Stéfanie Primon Muraro, Gabriela Fabiano de Souza, Mariene R. Amorim, Renata Sesti‐Costa, Luciana S. Mofatto, Julia Forato, Priscilla P. Barbosa, Daniel A. Toledo-Teixeira, Karina Bispo-dos-Santos, Pierina Lorencini Parise, Natália S. Brunetti, Josélia Cristina Oliveira Moreira, Vitor Antonio da Costa, Daniela Máira Cardozo, Maria Luíza Moretti, Sı́lvia de Barros-Mazon, Gabriela Felix Marchesi, Christiane Ambrosio, Fernando Rosado Spilki, Valéria Correia de Almeida, André Schwambach Vieira, Lair Zambon, Alessandro S. Farias, Marcelo Addas‐Carvalho, Bruno Deltreggia Benites, Rafael Elias Marques, Éster Cerdeira Sabino, Andrea B. Von Zuben, Scott C. Weaver, Nuno R. Faria, Fabiana Granja, Rodrigo Nogueira Angerami, José Luiz Proença-Módena,

Respiratory viral infections research

A SARS-CoV-2 B.1.1.7 variant of concern (VOC) has been associated with increased transmissibility, hospitalization, and mortality. This study aimed to explore the factors associated with B.1.1.7 VOC infection in the context of vaccination. On March 2021, we detected SARS-CoV-2 RNA in nasopharyngeal samples from 14 of 22 individuals vaccinated with a single-dose of ChAdOx1 (outbreak A, n = 26), and 22 of 42 of individuals with two doses of the CoronaVac vaccine (outbreak B, n = 52) for breakthrough infection rates for ChAdOx1 of 63.6% and 52.4% for CoronaVac. The outbreaks were caused by two independent clusters of the B.1.1.7 VOC. The serum of PCR-positive symptomatic SARS-CoV-2-infected individuals had ~1.8-3.4-fold more neutralizing capacity against B.1.1.7 compared to the serum of asymptomatic individuals. These data based on exploratory analysis suggest that the B.1.1.7 variant can infect individuals partially immunized with a single dose of an adenovirus-vectored vaccine or fully immunized with two doses of an inactivated vaccine, although the vaccines were able to reduce the risk of severe disease and death caused by this VOC, even in the elderly.